Patient
Measured CrCl from timed urine (preferred in ARC)
ICU dose calculator
Method, references and review
Scope
Adults aged 18 and over. Four kinds of support, each with different inputs: first-dose proposals, maintenance doses, level-based adjustment (vancomycin only), and emergency dose reference. Not for children or peritoneal dialysis. Doses are not adjusted for pregnancy; the eclampsia magnesium row is an emergency reference only. No patient data is saved; favourites and the theme are the only things remembered on this device.
How the numbers are calculated
- Ideal weight (Devine):
50 (male) or 45.5 (female) + 0.9055 × (height cm − 152.4). Adjusted weight:ideal + 0.4 × (actual − ideal). - Creatinine clearance (Cockcroft–Gault):
(140 − age) × weight ÷ (72 × creatinine), × 0.85 in women. Weight is actual if below ideal, ideal up to 120% of ideal, adjusted above that. - Measured clearance:
urine creatinine × urine volume ÷ (serum creatinine × minutes). Used in place of the estimate whenever entered. ARC flag at 130 mL/min; ARC-tier doses are applied only when the clearance was measured. Dose rules compare the unrounded clearance against explicit thresholds; it is displayed to one decimal place. - Vancomycin: clearance (Matzke)
(0.689 × CrCl + 3.66) × 0.06 L/h; daily dose = target AUC × clearance; volume 0.7 L/kg; infusion no faster than 10 mg/min, 60 min minimum. Measured AUC from two levels uses first-order (Sawchuk–Zaske) equations. - Aminoglycosides: fixed mg/kg dose, interval 24, 36 or 48 h at CrCl 60, 40 and 20 mL/min.
- Colistin: Nation 2017 look-up table for a target average level of 2 mg/L.
- Digoxin: clearance (Koup–Jusko)
1.303 × CrCl + 40(20 in moderate–severe heart failure) mL/min; dose = target level × clearance × 1.44 ÷ bioavailability. - Infusions:
mL/h = dose × weight × 60 ÷ concentration, dropping weight or the 60 where the unit has no kg or is per hour.
Sources
- ASHP/IDSA/PIDS/SIDP vancomycin therapeutic monitoring guideline, 2020.
- Nicolau et al., extended-interval aminoglycoside (Hartford) programme, 1995; Hamilton Health Sciences aminoglycoside dosing.
- Nation et al., Clin Infect Dis 2017; international consensus guidelines for the optimal use of the polymyxins, 2019.
- Koup and Jusko, Clin Pharmacol Ther 1975 (digoxin).
- SCCM PADIS guideline 2018; Surviving Sepsis Campaign 2021; AHA ACLS 2020.
- Product labels and SmPCs for renal dose schedules (meropenem, imipenem, piperacillin–tazobactam, cefepime, ceftazidime, teicoplanin, levofloxacin, fluconazole, acyclovir and others).
- Bilbao-Meseguer 2021 and Sime 2022 for levetiracetam in augmented renal clearance.
Release criteria
The prototype banner comes off only when all of these are met: every dose-table line approved by an intensivist and a clinical pharmacist; unit dilutions and stocked products entered by pharmacy; the documented test cases passing on the release build; primary-source verification complete for every clinical rule; and the institution's regulatory position recorded.
Review before clinical use
Every dose, dilution and renal schedule in this tool should be checked and signed by an ICU consultant or clinical pharmacist of the unit. Export the full table, review it line by line, and keep the signed copy with the tablet.